MedTrace Logo

Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI

NCT03182855 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-06-28

No results posted yet for this study

Summary

This randomized, controlled trial compares the anti-thrombotic effect of cangrelor and ticagrelor on platelet activity in patients with acute ST-elevation myocardial infarction.

Patients will receive either prehospital ticagrelor (180 mg - crushed) or in-hospital cangrelor (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) followed by 180 mg ticagrelor.

The primary study end-point is platelet reactivity at sheath insertion, at the end of the PCI procedure (before sheath removal) and two hours after PCI is initiated. The secondary end-point is the proportion of patients with inappropriate or harmful P2Y12 administration.

Conditions

Interventions

DRUG

Ticagrelor

ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.

DRUG

Cangrelor Tetrasodium

Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jacob T Sorensen, MD, PhD · Aarhus University Hospital, Department of Cardiology, Skejby

  • Steen D Kristensen, MD, DMSc · Aarhus University Hospital, Department of Cardiology, Skejby

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2019-06-01
Completion
2019-08-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03182855 on ClinicalTrials.gov